BIOCRYST PHARMACEUTICALS INC Uncategorized Contracts & Agreements

Drug/Drug Candidate (Filed With SEC on February 27, 2023)

Cash and cash equivalents (Filed With SEC on November 4, 2022)

Amendment, dated August 10, 2022, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on August 25, 2022)

Cash and cash equivalents (Filed With SEC on August 5, 2022)

EX-10.14 EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104 (Filed With SEC on February 28, 2022)

EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104 (Filed With SEC on February 28, 2022)

EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104 (Filed With SEC on February 28, 2022)

Amendment, dated August 27, 2021, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on September 1, 2021)

Amendment, dated August 31, 2020, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on September 3, 2020)

Cash and cash equivalents (Filed With SEC on May 11, 2020)

Drug/Drug Candidate (Filed With SEC on March 13, 2020)

Cash and cash equivalents (Filed With SEC on November 8, 2019)

Amendment dated as of September 23, 2019 to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on September 26, 2019)

Cash and cash equivalents (Filed With SEC on August 8, 2019)

Cash and cash equivalents (Filed With SEC on May 9, 2019)

Financial Statements (Filed With SEC on November 8, 2018)

Contract dated as of September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Centers for Disease Control and Prevention (Filed With SEC on September 6, 2018)

Cash and cash equivalents (Filed With SEC on May 9, 2018)

Cash and cash equivalents (Filed With SEC on November 8, 2017)

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS, IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. (Filed With SEC on November 8, 2016)

Statement of Work BioCryst Pharmaceuticals Contract HHSO100201500007C BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies (Filed With SEC on August 8, 2016)

Pursuant to 17 CFR 20.24b-2, confidential information has been omittedin places marked "***" and has been filed separately with the Securities and Exchange Commission pursuant to... (Filed With SEC on November 6, 2015)

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked *** and has been filed separately with the Securities and Exchange Commission pursuant to a... (Filed With SEC on August 7, 2015)

1. DEFINITIONS AND INTERPRETATION (Filed With SEC on August 7, 2015)

Cash and cash equivalents (Filed With SEC on November 7, 2014)

Exhibit A (ProprietaryInformation and Inventions Agreement) EMPLOYEES PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT (Filed With SEC on March 10, 2014)